Cinclus Pharma Appoints Gösta Hiller as Chief Operating Officer
Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for gastroesophageal reflux disease (“GERD”), today announced the appointment of Gösta Hiller as Chief Operating Officer (COO). Gösta has extensive and broad experience in the pharmaceutical industry and most recently from SDS Life Science where he was head of Clinical Project Management from 2017 to 2019 and COO from 2019 to late 2021.
” The company is delighted in having recruited Gösta Hiller to Cinclus Pharma” said Christer Ahlberg, CEO. "Gösta will with his broad experience in drug development and project management provide competence to lead the operative work from phase II and all the way to registration of Linaprazan glurate. Gösta had a leading role in the successful MAA submission of Sedana Medical’s product Sedaconda and this experience is highly needed at this stage of our Company development.
Gösta Hiller, started working at AstraZeneca as a Senior Research Scientist in 2001, moved into clinical development in 2006 where he gained hands on experience in clinical study design, clinical development planning and accountability for all regulatory documentation in several drug development projects and coordinated several global development teams at AstraZeneca as Global Project Manager. Moreover, Gösta has also worked with RWE-data (Real World Evidence) at QRC Stockholm. He joins most recently from SDS Life Science, a pharmaceutical consultant company, where he has supported several SME companies in clinical phase, and he has been fundamental for the build-up of the company as head of Clinical Project Management and COO during 2017 to 2021.
” I have high expectations on the company and on our candidate drug linaprazan glurate so I feel very enthusiastic and also honored to assume the COO position for Cinclus Pharma”, Gösta stated.” The teamwork and awesome spirit in the company makes it easy to contribute to the buildup and development of Cinclus Pharma”, he concluded.
For additional information, please contact:
Christer Ahlberg, CEO
Phone: +46 70 675 33 30
Gösta Hiller, COO
Phone: +46 72 372 59 58
About Cinclus Pharma and its lead candidate drug linaprazan glurate (former X842)
Cinclus Pharma AB is a clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Its drug candidate linaprazan glurate represents a novel class of drugs, Potassium Competitive Acid Blocker (P-CAB), and is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. The beneficial safety and pharmacokinetic properties of linaprazan glurate have been documented in phase I studies. The Phase 2 study is ongoing in Europe and the US. Linaprazan glurate is a prodrug of the P-CAB linaprazan, developed originally by AstraZeneca. Linaprazan has been evaluated in 23 phase I, and two phase II studies in a total of approximately 2,500 subjects. Linaprazan glurate is being developed for treatment of severe Gastroesophageal reflux disease (GERD)and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs.
Based on epidemiological data, the estimated size of this target population is 18.5 million and carries a Blockbuster potential (estimated sales exceeding USD 1 bn). The Company management has extensive experience from the pharmaceutical industry with special focus on the GI pharmaceutical area with experience from AstraZeneca and Novartis. For more information www.cincluspharma.com
Gastroesophageal reflux disease (GERD) is a digestive disease that affects the lower esophageal sphincter (LES), the ring of muscle between the esophagus and stomach, causing retrograde flow of gastric content into the esophagus. This leads to erosions, acid regurgitations and heart burn. About 175 million people of the adult population in North America and Europe suffer from reflux disease. The global acid reflux market is dominated by proton-pump inhibitors (PPIs). On average 5-10% of eGERD Grades A and B and approximately 30% of patients with eGERD Grades C and D are unhealed after eight weeks on PPIs, and 78% of all GERD patients experience nocturnal symptoms despite PPIs - resulting in quality-of-life issues. More than 20% of all GERD patients take PPIs twice daily to overcome the incomplete symptom relief or supplement their treatment with over the counter-remedies. Despite frequent off-label prescription of high dosage PPIs, many patients still suffer from poor symptom control indicating a clear need for better drugs to treat severe GERD.